Avedro, Inc.   Report issue

For profit Phase 3 Phase 4
Founded: Cambridge Massachusetts United States (2009)
Status: Acquired by Glaukos Corporation (2019)

Organization Overview

First Clinical Trial
2009
NCT00647699
First Marketed Drug
2016
riboflavin
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Avedro, Inc. | AVEDRO INC

Active Ingredients

Marketed Drugs (1)

riboflavin (2016)

Drugs in Phase 4 Trials (1)

riboflavin (6 trials)

Drugs in Phase 3 Trials (1)

ribavirin (virazole) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astigmatism (Phase 2)

Corneal Diseases (Phase 3)

Dilatation, Pathologic (Phase 3)

Hyperopia (Phase 2)

Keratoconus (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 2